Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

  • The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024
  • The collaboration supports Teva's Pivot to Growth strategy and adds to the company’s biosimilar portfolio
  • Both companies reaffirm their shared commitment to making high-quality, affordable treatments accessible to patients worldwide

TEL AVIV, ISRAEL and MADRID, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate. This marks the second agreement between the two companies, reinforcing the solid foundation of the collaborative efforts that commenced in April 2024.

The global agreement to develop an additional oncology biosimilar further strengthens the alliance between Teva and mAbxience, underscoring the shared goal to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care. By leveraging each company’s unique expertise and resources, the collaboration continues to drive innovation and accessibility in healthcare to create solutions for patients worldwide.

The licensing agreement includes exclusive rights for multiple markets, including Europe and the United States, and aligns with mAbxience's strategy for global expansion. The collaboration reflects Teva's progress advancing its Pivot to Growth strategy by adding a new biosimilar to the company’s broad portfolio of biosimilars, through focused partnerships and business development efforts.

Similar to the initial contract, under the terms of this agreement, mAbxience will lead the development and production of the biosimilar, utilizing its state-of-the-art, cGMP-compliant facilities in Spain and Argentina. Teva will manage regulatory approvals and oversee commercialization in the designated markets, ensuring that patients around the world gain access to this oncology treatment.

Angus Grant, PhD, Executive Vice President of Business Development at Teva, said, “We are excited to deepen our collaboration with mAbxience. This agreement not only strengthens our alliance but also highlights our shared dedication to expanding access to critical oncology treatments. This collaboration with mAbxience reflects Teva’s ideal strategic partnership model to optimize development costs, apply our regulatory expertise and leverage our extensive commercial capabilities to bring new treatment options to people living with serious medical conditions.”

“Building on our first agreement with Teva signed earlier this year, this second collaboration is a testament to the strength of our partnership and the shared vision of both companies,” added Jurgen Van Broeck, CEO of mAbxience. “This agreement reinforces our commitment to making high-quality biosimilars accessible and improving healthcare outcomes on a global scale.”

About Teva

Teva (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.

About mAbxience

mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com) or connect with us on LinkedIn.

Teva Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to effectively execute and expand our collaboration with mAbxience for the development of oncology biosimilar candidates; our ability to lead the regulatory processes and commercialization of such biosimilar candidates in the designated markets; risks that regulatory approvals and other requirements may delay the development and commercialization of the biosimilar candidates; our ability to successfully launch and execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in this press release, in our Quarterly Report for the second quarter of 2024, and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

mAbxience contacts:

Media
Miguel Martínez-Cava, Global External Communication Manager: miguel.martinezcava@mabxience.com

Teva contacts

Media Contacts
Kelley Dougherty +1 (973) 832-2810
Eden Klein +972 (3) 906-2645

IR Contacts
Ran Meir +1 (267) 468-4475
Yael Ashman +972 (3) 914-8262
Sanjeev Sharma +1 (973) 658 2700


Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

THỦ THUẬT HAY

Hướng dẫn một số cách kiểm tra nhanh số điện thoại

Có nhiều cách để biết số điện thoại đang dùng thông qua mã USSD, hoặc thông qua 3G/4G với trình duyệt với máy tính bảng hoặc qua cục phát Wi-Fi hotspot.

Đăng ký dữ liệu 4G lướt web, Facebook và YouTube miễn phí dành cho SIM MobiFone và Viettel

Với những lợi ích của SIM 4G mang lại như: dễ sử dụng, tốc độ truy cập vượt trội... Chắc chắn bạn cũng mong muốn trải nghiệm tốc độ mạng 4G như thế nào? Tuy nhiên phí đăng ký 4G khá là cao, nhưng bây giờ TECHRUM chia

Bạn đã biết đến 7 tính năng ẩn trên smartphone chưa?

Không thể phủ nhận quảng cáo gây ảnh hưởng khá nhiều đến phần nhìn cũng như độ trải nghiệm ứng dụng: che mất nội dung, các quảng cáo có hình ảnh nhạy cảm,...

Tạo ghi chú ngay trên màn hình khóa cực tiện lợi với tinh chỉnh Notepad

Notepad là một tinh chỉnh mới từ nhà phát triển NeinZedd9 và AppleBetas, cho phép người dùng tạo ghi chú trên màn hình khóa thông qua một tiện ích riêng biệt trong bất kỳ thời điểm nào với thao tác cực kỳ đơn giản, chỉ

Hàng loạt số rác sẽ được tự động chặn với ứng dụng TrueCaller

Mặc dù các nhà mạng đã có các chính sách để ngăn chặn sim rác, nhưng thực tế vẫn rất nhiều người dùng bị làm phiền bởi tin nhắn và cuộc gọi lừa đảo. Dù bạn đã chặn nhưng không thể chặn hết số lượng sim rác làm phiền.

ĐÁNH GIÁ NHANH

Đánh giá Oukitel U7 Plus: Smartphone giá rẻ dưới 2 triệu

Oukitel U7 Plus có thiết kế khá giống với iPhone 6, phần mặt lưng của sản phẩm được bo tròn ở các cạnh và được vát cong để máy khi cầm sẽ ôm tay hơn.

Đánh giá chi tiết thiết kế vận hành của xe Ford Everest 2019

Điểm thay đổi đáng chú ý nhất trên Ford Everest 2019 đến từ trang bị động cơ 2.0L TDCi Bi-Turbo công suất 213 mã lực, mô men xoắn cực đại 500 Nm, đi kèm hộp số tự động 10 cấp tương tự như trên Ford Ranger Raptor mới.

Đánh giá ThinkPad X1 Yoga: màn hình OLED tuyệt vời, hiệu năng tốt, pin trung bình, giá cao

Chiếc laptop doanh nhân thiết kế màn hình xoay 360 độ này cũng đã bước sang thế hệ 2, năm nay Lenovo cải tiến thiết kế bàn phím trồi sụt khi lật mở, cấu hình mới và tiếp tục trang bị màn hình OLED rất đẹp. Chiếc máy